These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 33586097

  • 1. Correlations between whole body volumetric parameters of 68Ga-PSMA PET/CT and biochemical-histopathological parameters in castration-naive and resistant prostate cancer patients.
    Yildirim ÖA, Gündoğan C, Can C, Poyraz K, Erdur E, Kömek H.
    Ann Nucl Med; 2021 May; 35(5):540-548. PubMed ID: 33586097
    [Abstract] [Full Text] [Related]

  • 2. The Added Value of 18F-FDG PET/CT Compared with 68Ga-PSMA PET/CT in Patients with Castration-Resistant Prostate Cancer.
    Chen R, Wang Y, Zhu Y, Shi Y, Xu L, Huang G, Liu J.
    J Nucl Med; 2022 Jan; 63(1):69-75. PubMed ID: 34980667
    [Abstract] [Full Text] [Related]

  • 3. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
    Schmidkonz C, Cordes M, Goetz TI, Prante O, Kuwert T, Ritt P, Uder M, Wullich B, Goebell P, Bäuerle T.
    Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
    [Abstract] [Full Text] [Related]

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Oct; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of Gallium-68 prostate-specific membrane antigen, positron emission tomography/computed tomography (GA-68 PSMA PET/CT) in recurrent prostate cancer: a retrospective review of initial clinical experience at Tygerberg Hospital.
    Sangiwa BA, Burger C, Ellmann A.
    Pan Afr Med J; 2024 Oct; 48():30. PubMed ID: 39220559
    [Abstract] [Full Text] [Related]

  • 6. Role of 68Ga-PSMA PET/CT parameters in treatment evaluation and survival prediction in prostate cancer patients compared with biochemical response assessment.
    Can C, Gündoğan C, Yildirim OA, Poyraz K, Güzel Y, Kömek H.
    Hell J Nucl Med; 2021 Oct; 24(1):25-35. PubMed ID: 33866336
    [Abstract] [Full Text] [Related]

  • 7. Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, (68)Ga-PSMA PET/CT, PSA, and PSA-density comparison study.
    Akkaya H, Dilek O, Özdemir S, Taş ZA, Öztürk İS, Gülek B.
    Diagn Interv Radiol; 2023 Sep 05; 29(5):647-655. PubMed ID: 37395389
    [Abstract] [Full Text] [Related]

  • 8. Assessment of volumetric parameters derived from 68Ga-PSMA PET/CT in prostate cancer patients with biochemical recurrence: an institutional experience.
    Okudan B, Coşkun N, Seven B, Atalay MA, Yildirim A, Görtan FA.
    Nucl Med Commun; 2021 Nov 01; 42(11):1254-1260. PubMed ID: 34284438
    [Abstract] [Full Text] [Related]

  • 9. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
    Rogic I, Golubic AT, Zuvic M, Smitran T, Jukic N, Gamulin M, Kastelan Z, Huic D.
    Nucl Med Rev Cent East Eur; 2024 Nov 01; 27(0):6-12. PubMed ID: 38680016
    [Abstract] [Full Text] [Related]

  • 10. Comparison of quantitative whole body PET parameters on [68Ga]Ga-PSMA-11 PET/CT using ordered Subset Expectation Maximization (OSEM) vs. bayesian penalized likelihood (BPL) reconstruction algorithms in men with metastatic castration-resistant prostate cancer.
    Ayati N, McIntosh L, Buteau J, Alipour R, Pudis M, Daw N, Jackson P, Hofman MS.
    Cancer Imaging; 2024 May 06; 24(1):57. PubMed ID: 38711135
    [Abstract] [Full Text] [Related]

  • 11. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.
    Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, Scarpa L, di Santo G, Roig LG, Maffey-Steffan J, Horninger W, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2017 Jun 06; 44(6):941-949. PubMed ID: 28138747
    [Abstract] [Full Text] [Related]

  • 12. The superior detection rate of total-body [68Ga]Ga-PSMA-11 PET/CT compared to short axial field-of-view [68Ga]Ga-PSMA-11 PET/CT for early recurrent prostate cancer patients with PSA < 0.2 ng/mL after radical prostatectomy.
    Wang Y, Dong L, Zhao H, Li L, Huang G, Xue W, Liu J, Chen R.
    Eur J Nucl Med Mol Imaging; 2024 Jul 06; 51(8):2484-2494. PubMed ID: 38514483
    [Abstract] [Full Text] [Related]

  • 13. Direct Patlak Reconstruction of [68Ga]Ga-PSMA PET for the Evaluation of Primary Prostate Cancer Prior Total Prostatectomy: Results of a Pilot Study.
    Rasul S, Geist BK, Einspieler H, Fajkovic H, Shariat SF, Schmitl S, Mitterhauser M, Bartosch R, Langsteger W, Baltzer PAT, Beyer T, Ferrara D, Haug AR, Hacker M, Rausch I.
    Int J Mol Sci; 2023 Sep 05; 24(18):. PubMed ID: 37761975
    [Abstract] [Full Text] [Related]

  • 14. Determination of whole-body tumour burden on [68Ga]PSMA-11 PET/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy.
    Michalski K, Mix M, Meyer PT, Ruf J.
    Nuklearmedizin; 2019 Dec 05; 58(6):443-450. PubMed ID: 31724145
    [Abstract] [Full Text] [Related]

  • 15. 68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer.
    Vinsensia M, Chyoke PL, Hadaschik B, Holland-Letz T, Moltz J, Kopka K, Rauscher I, Mier W, Schwaiger M, Haberkorn U, Mauer T, Kratochwil C, Eiber M, Giesel FL.
    J Nucl Med; 2017 Dec 05; 58(12):1949-1955. PubMed ID: 28637799
    [Abstract] [Full Text] [Related]

  • 16. (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.
    Sachpekidis C, Eder M, Kopka K, Mier W, Hadaschik BA, Haberkorn U, Dimitrakopoulou-Strauss A.
    Eur J Nucl Med Mol Imaging; 2016 Jul 05; 43(7):1288-99. PubMed ID: 26753602
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting response to second-generation androgen receptor axis-targeted therapy, and the prognosis in metastatic hormone-refractory prostate cancer patients.
    Oruç Z, Güzel Y, Ebinç S, Kömek H, Küçüköner M, Kaplan MA, Oruç İ, Urakçi Z, Işikdoğan A.
    Nucl Med Commun; 2021 Dec 01; 42(12):1336-1346. PubMed ID: 34366407
    [Abstract] [Full Text] [Related]

  • 18. Clinical Factors That Influence Repeat 68Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative 68Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study.
    Thin P, Hotta M, Gafita A, Grogan T, Czernin J, Calais J, Sonni I.
    J Nucl Med; 2024 Oct 01; 65(10):1571-1576. PubMed ID: 39168522
    [Abstract] [Full Text] [Related]

  • 19. 68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer.
    Schmidkonz C, Cordes M, Schmidt D, Bäuerle T, Goetz TI, Beck M, Prante O, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P.
    Eur J Nucl Med Mol Imaging; 2018 Oct 01; 45(11):1862-1872. PubMed ID: 29725716
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of 68Ga-PSMA PET/CT with volumetric parameters for staging of prostate cancer patients.
    Aksu A, Karahan Şen NP, Tuna EB, Aslan G, Çapa Kaya G.
    Nucl Med Commun; 2021 May 01; 42(5):503-509. PubMed ID: 33560717
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.